A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


March 4, 2014

Monthly PrEP Injections Show Promise in Female Monkeys

CROI 2014Monthly injections of the long-acting investigational antiretroviral GSK744 given to pigtail macaques prevented vaginal acquisition of SIV, which is the simian cousin of HIV. The study raises hopes that HIV-negative women may eventually have an alternative to taking daily pills for pre-exposure prophylaxis (PrEP) to prevent the spread of HIV, and one that would help address the critical issue of drug adherence. Investigators from the Centers for Disease Control and Prevention (CDC) presented their findings at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston.

The researchers gave injections of GSK744 to six macaques every four weeks and gave injections of a placebo to another six primates on the same schedule. All the monkeys were exposed to SIV vaginally twice a week, totaling 22 exposures in all.

All six of the primates that received the placebo injections acquired SIV, following a median of four exposures to the virus. None of the six macaques that received injections of the ARV were infected during the 22 exposures, nor did they show signs of the virus 20 weeks after the final injection of GSK744.

The study’s results, the researchers find, support human trials to study GSK744’s potential as a form of PrEP for women.

Search: PrEP, pre-exposure prophylaxis, GSK744, SIV, HIV, Conference on Retroviruses and Opportunistic Infections, CROI, Centers for Disease Control and Prevention, CROI.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.